Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice
Petra Huehnchen, Hannah Muenzfeld, Wolfgang Boehmerle, Matthias Endres, Petra Huehnchen, Hannah Muenzfeld, Wolfgang Boehmerle, Matthias Endres
Abstract
The microtubule-stabilizing agent paclitaxel frequently leads to chemotherapy-induced peripheral neuropathy (CIN), which further increases the burden of disease and often necessitates treatment limitations. The pathophysiology of CIN appears to involve both "upstream" effects including altered intracellular calcium signaling and activation of calcium dependent proteases such as calpain as well as subsequent "downstream" neuro-inflammatory reactions with cytokine release and macrophage infiltration of dorsal root ganglia. In this study, we aimed to investigate whether these processes are linked by the pro-inflammatory cytokine interleukin-6 (IL-6). We observed that paclitaxel exposure induced IL-6 synthesis in cultured sensory neurons from postnatal Wistar rats, which could be prevented by co-treatment with a calpain inhibitor. This suggests a calcium dependent process. We demonstrate that adult C57BL/6 mice deficient in IL-6 are protected from developing functional and histological changes of paclitaxel-induced neuropathy. Furthermore, pretreatment with an IL-6-neutralizing antibody resulted in the prevention of paclitaxel-induced neuropathy in C57BL/6 mice. Electrophysiological data from our preclinical model was adequately reflected by measurements of patients undergoing paclitaxel therapy for ovarian cancer. In this cohort, measured Il-6 levels correlated with the severity of neuropathy. Our findings demonstrate that IL-6 plays a pivotal role in the pathophysiology of paclitaxel-induced neuropathy per se and that pharmacological or genetic interference with this signaling pathway prevents the development of this potentially debilitating adverse effect. These findings provide a rationale for a clinical trial with IL-6 neutralizing antibodies to prevent dose-limiting neurotoxic adverse effects of paclitaxel chemotherapy.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
References
- Seretny M, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461–2470. doi: 10.1016/j.pain.2014.09.020.
- Majithia N, et al. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Supportive Care Cancer. 2016;24:1439–1447. doi: 10.1007/s00520-015-3063-4.
- Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci. Lett. 2015;596:90–107. doi: 10.1016/j.neulet.2014.10.014.
- Lees JG, et al. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur. J. Cancer. 2017;73:22–29. doi: 10.1016/j.ejca.2016.12.006.
- Ale A, et al. Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model. Exp. Neurol. 2014;253:165–173. doi: 10.1016/j.expneurol.2013.12.020.
- Kiguchi N, et al. The critical role of invading peripheral macrophage-derived interleukin-6 in vincristine-induced mechanical allodynia in mice. Eur. J. Pharmacol. 2008;592:87–92. doi: 10.1016/j.ejphar.2008.07.008.
- Andratsch M, et al. A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J. Neurosci. 2009;29:13473–13483. doi: 10.1523/JNEUROSCI.1822-09.2009.
- Quarta S, et al. Genetic evidence for an essential role of neuronally expressed IL-6 signal transducer gp130 in the induction and maintenance of experimentally induced mechanical hypersensitivity in vivo and in vitro. Mol. Pain. 2011;7:73. doi: 10.1186/1744-8069-7-73.
- Starkweather A. Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral neuropathy in women after breast cancer treatment. Nurs. Res. Pract. 2010;2010:281531.
- San-Miguel J, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014;123:4136–4142. doi: 10.1182/blood-2013-12-546374.
- Guo Y, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin. Cancer Res. 2010;16:5759–5769. doi: 10.1158/1078-0432.CCR-10-1095.
- Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J. Thorac. Oncol. 2014;9:974–982. doi: 10.1097/JTO.0000000000000193.
- Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin. Proc. 1994;69:341–345. doi: 10.1016/S0025-6196(12)62219-8.
- Park SB, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA: A Cancer J. Clinicians. 2013;63:419–437.
- Boehmerle W, et al. Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc. Natl Acad. Sci. USA. 2006;103:18356–18361. doi: 10.1073/pnas.0607240103.
- Boehmerle W, et al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc. Natl Acad. Sci. USA. 2007;104:11103–11108. doi: 10.1073/pnas.0701546104.
- Goldenberg SS, De Boni U. Pure population of viable neurons from rabbit dorsal root ganglia, using gradients of Percoll. J. Neurobiol. 1983;14:195–206. doi: 10.1002/neu.480140304.
- Capela JP, et al. Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia. Neuroscience. 2006;139:1069–1081. doi: 10.1016/j.neuroscience.2006.01.007.
- Boehmerle W, Huehnchen P, Lee SLL, Harms C, Endres M. TRPV4 inhibition prevents paclitaxel-induced neurotoxicity in preclinical models. Exp. Neurol. 2018;306:64–75. doi: 10.1016/j.expneurol.2018.04.014.
- Kopf M, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339–342. doi: 10.1038/368339a0.
- Smith SB, Crager SE, Mogil JS. Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains. Life Sci. 2004;74:2593–2604. doi: 10.1016/j.lfs.2004.01.002.
- Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods. 2007;39:175–191. doi: 10.3758/BF03193146.
- Bonapace L, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515:130–133. doi: 10.1038/nature13862.
- Zhao Y, Xiao X, Frank SJ, Lin HY, Xia Y. Distinct mechanisms of induction of hepatic growth hormone resistance by endogenous IL-6, TNF-alpha, and IL-1beta. Am. J. Physiol. Endocrinol. Metab. 2014;307:E186–E198. doi: 10.1152/ajpendo.00652.2013.
- Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 2007;27:10695–10702. doi: 10.1523/JNEUROSCI.2178-07.2007.
- Miyamoto M, et al. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J. Immunol. 2003;170:4665–4672. doi: 10.4049/jimmunol.170.9.4665.
- Cunha TM, et al. An electronic pressure-meter nociception paw test for mice. Braz. J. Med. Biol. Res. 2004;37:401–407. doi: 10.1590/S0100-879X2004000300018.
- Wang MS, Davis AA, Culver DG, Glass JD. WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann. Neurol. 2002;52:442–447. doi: 10.1002/ana.10300.
- Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 2012;9:676. doi: 10.1038/nmeth.2019.
- More HL, Chen J, Gibson E, Donelan JM, Beg MF. A semi-automated method for identifying and measuring myelinated nerve fibers in scanning electron microscope images. J. Neurosci. Methods. 2011;201:149–158. doi: 10.1016/j.jneumeth.2011.07.026.
- Zaimi A, et al. AxonSeg: open source software for axon and myelin segmentation and morphometric analysis. Front. Neuroinformatics. 2016;10:37. doi: 10.3389/fninf.2016.00037.
- Cavaletti G, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;61:1297–1300. doi: 10.1212/01.WNL.0000092015.03923.19.
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J. Pharmacol. Pharmacotherapeutics. 2010;1:94–99. doi: 10.4103/0976-500X.72351.
- Zhang H, et al. Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. J. Pain. 2016;17:775–786. doi: 10.1016/j.jpain.2016.02.011.
- Schlecker C, et al. Neuronal calcium sensor-1 enhancement of InsP3 receptor activity is inhibited by therapeutic levels of lithium. J. Clin. Invest. 2006;116:1668–1674. doi: 10.1172/JCI22466.
- Mo M, Erdelyi I, Szigeti-Buck K, Benbow JH, Ehrlich BE. Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. FASEB J. 2012;26:4696–4709. doi: 10.1096/fj.12-214643.
- Juretic N, Garcia-Huidobro P, Iturrieta JA, Jaimovich E, Riveros N. Depolarization-induced slow Ca2+ transients stimulate transcription of IL-6 gene in skeletal muscle cells. Am. J. Physiol. Cell Physiol. 2006;290:C1428–C1436. doi: 10.1152/ajpcell.00449.2005.
- Li C, et al. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J. Biol. Chem. 2010;285:16096–16104. doi: 10.1074/jbc.M109.072694.
- Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell. Biol. 1990;10:2327–2334. doi: 10.1128/MCB.10.5.2327.
- Boehmerle W, Huehnchen P, Endres M. Chemotherapy-induced neuropathy. Der Nervenarzt. 2015;86:156–160. doi: 10.1007/s00115-014-4126-3.
- Todd J, Simpson P, Estis J, Torres V, Wub AH. Reference range and short- and long-term biological variation of interleukin (IL)-6, IL-17A and tissue necrosis factor-alpha using high sensitivity assays. Cytokine. 2013;64:660–665. doi: 10.1016/j.cyto.2013.09.018.
- Zhou YQ, et al. Interleukin-6: an emerging regulator of pathological pain. J. Neuroinflammation. 2016;13:141. doi: 10.1186/s12974-016-0607-6.
- DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J. Interferon Cytokine Res. 1996;16:695–700. doi: 10.1089/jir.1996.16.695.
- Ramer MS, Murphy PG, Richardson PM, Bisby MA. Spinal nerve lesion-induced mechanoallodynia and adrenergic sprouting in sensory ganglia are attenuated in interleukin-6 knockout mice. Pain. 1998;78:115–121. doi: 10.1016/S0304-3959(98)00121-3.
- Murphy PG, et al. Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Eur. J. Neurosci. 1999;11:2243–2253. doi: 10.1046/j.1460-9568.1999.00641.x.
- Murakami T, et al. Anti-interleukin-6 receptor antibody reduces neuropathic pain following spinal cord injury in mice. Exp. Therapeutic Med. 2013;6:1194–1198. doi: 10.3892/etm.2013.1296.
- Boehmerle W, Huehnchen P, Peruzzaro S, Balkaya M, Endres M. Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci. Rep. 2014;4:6370. doi: 10.1038/srep06370.
- Gadient RA, Otten U. Postnatal expression of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) mRNAs in rat sympathetic and sensory ganglia. Brain Res. 1996;724:41–46. doi: 10.1016/0006-8993(96)00264-8.
- Murphy PG, Grondin J, Altares M, Richardson PM. Induction of interleukin-6 in axotomized sensory neurons. J. Neurosci. 1995;15(7 Pt 2):5130–5138. doi: 10.1523/JNEUROSCI.15-07-05130.1995.
- Wei XH, et al. The up-regulation of IL-6 in DRG and spinal dorsal horn contributes to neuropathic pain following L5 ventral root transection. Exp. Neurol. 2013;241:159–168. doi: 10.1016/j.expneurol.2012.12.007.
- Zang Y, et al. Calpain-2 contributes to neuropathic pain following motor nerve injury via up-regulating interleukin-6 in DRG neurons. Brain, Behav., Immun. 2015;44:37–47. doi: 10.1016/j.bbi.2014.08.003.
- Godwin P, et al. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front. Oncol. 2013;3:120. doi: 10.3389/fonc.2013.00120.
- Arruda JL, Colburn RW, Rickman AJ, Rutkowski MD, DeLeo JA. Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic pain. brain Res. Mol. Brain Res. 1998;62:228–235. doi: 10.1016/S0169-328X(98)00257-5.
- Konig C, et al. Involvement of spinal IL-6 trans-signaling in the induction of hyperexcitability of deep dorsal horn neurons by spinal tumor necrosis factor-alpha. J. Neurosci. 2016;36:9782–9791. doi: 10.1523/JNEUROSCI.4159-15.2016.
- Zhang H, Yoon SY, Zhang H, Dougherty PM. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J. Pain. 2012;13:293–303. doi: 10.1016/j.jpain.2011.12.002.
- Li D, et al. Up-regulation of CX3CL1 via nuclear factor-kappaB-dependent histone acetylation is involved in paclitaxel-induced peripheral neuropathy. Anesthesiology. 2015;122:1142–1151. doi: 10.1097/ALN.0000000000000560.
- Huang ZZ, et al. CX3CL1-mediated macrophage activation contributed to paclitaxel-induced DRG neuronal apoptosis and painful peripheral neuropathy. Brain, Behav., Immun. 2014;40:155–165. doi: 10.1016/j.bbi.2014.03.014.
- Zhou J, Zhang C, Pan J, Chen L, Qi ST. Interleukin6 induces an epithelialmesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration. Mol. Med. Rep. 2017;15:4123–4131. doi: 10.3892/mmr.2017.6538.
- Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann. Neurol. 2017;81:772–781. doi: 10.1002/ana.24951.
- Castell JV, et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Biochem. 1988;177:357–361. doi: 10.1111/j.1432-1033.1988.tb14384.x.
Source: PubMed